Abstract:
PURPOSE: Phytase expression vector, pJPK has strong BJ27 promoter. Bacillus subtilis pJPK (KCTC 0526BP) transformed with pJPK expresses phytase highly, secrets expressed protein and is nontoxic to animal because of lacking endotoxin such as lipopolysaccharides. CONSTITUTION: Bacillus expression vector pJH27, having strong promoter BJ27, is ligated with 2.2 kb phytase gene originated from Bacillus amyloliquefaciens DS-11. The 2.2kb DNA includes SD sequence of phytase gene complementary to Bacillus subtilis 16S rRNA sequence (UCCUCC) for the overexpression of phytase. Resulting recombinant plasmid, pJPK, is introduced into E. coli JM83. Purified pJPK is transformed into Bacillus subtilis DB104 by protoplast transformation. Modified LB medium is consisted of 1% of potassium phosphate, 0.045% of magnesium sulfate, 4% of glucose, 1% of tryptone, 0.5% of yeast extract, 0.5% of NaCl and trace elements. 500-1000 unit of phytase is added to 1kg of animal feed. Animal experiment with porcine reveals that phytase produced from bacillus effectively degrades phytic acid in the animal feed.
Title translation:一种用于处理包含来自A A AN AN AN AN AN TING TING TING TING TING TING TING TING TING TING ROM ROM ROM ROM ROM ROM ROM ROM ROM ROM ROM ROM ROM ROM ROM ROM ROM ROM ROM ROM
Abstract:
본 발명은 화학식 1 및 화학식 2로 표시되는 플라보노이드 화합물 또는 이를 포함하는 고삼 추출물을 유효성분으로 함유하는 성기능 장애 개선용 조성물에 관한 것으로, 상기 조성물은 cGMP 포스포디에스테라제 저해활성을 가짐으로써 발기부전 또는 발기 기능 장애와 같은 성기능 장애를 개선하는데 사용할 수 있다. 화학식 1
(상기식에서, R 1 , R 2 , R 3 , R 4 및 점선은 하기 명세서에 나타낸 바와 같다.) 화학식 2
Abstract:
PURPOSE: A composition for the prevention and treatment of ischemic disease containing aloesin as an effective ingredient and a preparation containing the same is provided. Because aloesin as an aloe component has an excellent neuroprotective effect and nerve-ethological recovering effect, the composition containing the same can be effectively used in treatment of nerve cell and tissue damage caused by cerebral ischemia. CONSTITUTION: The composition for prevention and treatment of ischemia disease contains aloesin of the formula 1 £8-C-β -D-glucopyranosyl-7-hydroxy-5-methyl-2-(2-oxopropyl)-4H-1-benzopyran-4-one|, a pharmaceutically acceptable salt, hydrate or solvate or isomer and a pharmaceutically acceptable carrier thereof. The composition is formulated into a tablet, hard and soft gelatin capsule, liquid, suspension, injection, ointment, cream, gel or lotion. The composition is a neuroprotective composition for the prevention and treatment of ischemic apoplexy or concussion and a heart protecting composition for the prevention and treatment of ischemic myocardial infarction.
Abstract:
PURPOSE: Provided is a method for preparing novel pyrazolpyrimidine derivative represented by the formula(1) and its pharmaceutically acceptable salts or hydrates. A pharmaceutical composition containing it is used as a therapeutic agent for impotency by inhibition of phosphodiesterase V. CONSTITUTION: The novel pyrazolpyrimidine derivative represented by the formula(1), wherein R1 and R2 are independently C1-C6 alkyl or C3-C6 cycloalkyl; R3 is substituted or unsubstituted C1-C6 alkyl, C3-C6 cycloalkyl or C3-C6 alkenyl; and X is O or NR4 wherein R4 is hydrogen, OH or C1-C6 alkyl, C3-C6 cycloalkyl or C3-C6 alkenyl substituted or unsubstituted by alkoxy group. It is manufactured by the steps of: converting pyrazolopyrimidinone of the formula(2) into pyrazolopyrimidinethione of the formula(3) by thione reaction; chlorosulfonating the compound of the formula(3) into chlorosulfone compound of the formula(4) and letting the compound of formula(4) react with secondary amine to make the final compound of the formula(1).
Abstract:
PURPOSE: A composition for the prevention and treatment of ischemic disease containing aloesin as an effective ingredient and a preparation containing the same is provided. Because aloesin as an aloe component has an excellent neuroprotective effect and nerve-ethological recovering effect, the composition containing the same can be effectively used in treatment of nerve cell and tissue damage caused by cerebral ischemia. CONSTITUTION: The composition for prevention and treatment of ischemia disease contains aloesin of the formula 1 £8-C-β -D-glucopyranosyl-7-hydroxy-5-methyl-2-(2-oxopropyl)-4H-1-benzopyran-4-one|, a pharmaceutically acceptable salt, hydrate or solvate or isomer and a pharmaceutically acceptable carrier thereof. The composition is formulated into a tablet, hard and soft gelatin capsule, liquid, suspension, injection, ointment, cream, gel or lotion. The composition is a neuroprotective composition for the prevention and treatment of ischemic apoplexy or concussion and a heart protecting composition for the prevention and treatment of ischemic myocardial infarction.
Abstract:
PURPOSE: The titled inhibitor containing a Scutellaria baicalensis George extract as a main component is provided which has an effect on suppressing carcinogenesis and can be used for prevention of cancer generated in an organ in the body such as liver cancer, stomach cancer, esophageal cancer, lung cancer, breast cancer or the like. CONSTITUTION: This carcinogenesis inhibitor is obtained by extracting a Scutellaria baicalensis George and can suppress carcinogenesis by expression of glutathiones S-transferase(GST) Yc1/2 to transfer carcinogenic substances to nontoxicity before DNA of a cell is damaged. The agent can formulate to be administered orally or parenterally at a dose of 11 to 500mg/kg/day.
Abstract translation:目的:提供含有黄芩提取物作为主要成分的标题抑制剂,其具有抑制致癌作用的作用,并且可用于预防身体器官中产生的癌症,例如肝癌,胃癌,食管癌, 肺癌,乳腺癌等。 构成:这种致癌抑制剂是通过提取黄芩获得的,并且可以通过表达谷胱甘肽S-转移酶(GST)Yc1 / 2来抑制致癌作用,以在细胞DNA损伤之前将致癌物质转移到无毒性。 该制剂可以配制成口服或肠胃外给药,剂量为11至500mg / kg /天。
Abstract:
PURPOSE: Provided is a composition for treating sexual dysfunction which contains a flavonoid compound represented by the formula 1 or 2, and an extract of Sophora flavescens containing them, as active ingredients. The composition inhibits on cGMP-PDE5 and is thus useful for the prevention and treatment of sexual disfunction. CONSTITUTION: A composition for treating sexual dysfunction is characterized by containing, as active ingredients, a flavonoid compound represented by the formula 1 or 2, wherein R1 is a unsubstituted or hydroxy group-substituted linear or branched alkenyl group; R2 is hydrogen, hydroxy or C1-C3 alkoxy; R3 and R4 are individually hydrogen or a hydroxy group; and a dotted line represents single or double bond, and its pharmaceutically acceptable salt, hydrates, solvate, isomer or their mixture.